Table 2.
Premature discontinuation during extension study (safety population) of levomilnacipran ER 40–120 mg/day (n = 825)
| Patient status | n (%) |
|---|---|
| Completed open-label treatment | 384 (46.5) |
| Prematurely discontinued | 441 (53.5) |
| Reason for discontinuation | |
| Adverse event | 107 (13.0) |
| Insufficient therapeutic response | 56 (6.8) |
| Protocol violation | 67 (8.1) |
| Withdrawal of consent | 118 (14.3) |
| Lost to follow-up | 87 (10.5) |
| Other reasons | 6 (0.7) |
| Entered down-taper perioda | 490 (59.4) |
ER extended-release
aPatients completing 48 weeks of open-label treatment or prematurely discontinuing entered a dosage down-taper period of up to 4 weeks if medically appropriate